Medicines labeled for the same conditions
Alternatives to ceftazidime
21 other medicines are given the same way (intravenous) and in the same FDA class as ceftazidime or labeled mainly for the same use (bacterial infections); 4 are in its class, cephalosporin antibacterials: cefoxitin, ceftriaxone, cefuroxime and cefotaxime; the others include 2 beta lactamase inhibitors, 2 fluoroquinolone antibacterials and 2 penicillin-class antibacterials (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $1.44 per ceftriaxone 1 g vial (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as ceftazidime?
Bacterial infections lists all 51 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Ceftazidimecephalosporin antibacterial | this medicine | 3 labelers | $3.70 per vial 1 g vial | No | A presentation being discontinued |
| Cefoxitincephalosporin antibacterial · same class | Bacterial infections | 5 labelers | n/a | No | No current entry |
| Ceftriaxonecephalosporin antibacterial · same class | Bacterial infections | 7 labelers | $1.44 per vial 1 g vial | No | No current entry |
| Cefuroximecephalosporin antibacterial · same class | Bacterial infections | 2 labelers | n/a | No | No current entry |
| Cefotaximecephalosporin antibacterial · same class | Bacterial infections | 1 labeler | n/a | No | In shortage |
| Vancomycinglycopeptide antibacterial | Bacterial infections | 21 labelers | $2.31 per vial 500 mg vial | No | A presentation being discontinued |
| Piperacillin and tazobactambeta lactamase inhibitor | Bacterial infections | 15 labelers | $3.49 per vial 3.375 g vial | No | A presentation being discontinued |
| Levofloxacinfluoroquinolone antibacterial | Bacterial infections | 8 labelers | n/a | Yes | No current entry |
| Clindamycinlincosamide antibacterial | Bacterial infections | 6 labelers | n/a | Yes | In shortage |
| Ampicillinpenicillin-class antibacterial | Bacterial infections | 11 labelers | n/a | No | A presentation being discontinued |
| Linezolidoxazolidinone antibacterial | Bacterial infections | 9 labelers | n/a | No | No current entry |
| Ampicillin and sulbactambeta lactamase inhibitor | Bacterial infections | 7 labelers | n/a | No | No current entry |
| Azithromycinmacrolide antimicrobial | Bacterial infections | 7 labelers | n/a | No | A presentation being discontinued |
| Metronidazolenitroimidazole antimicrobial | Bacterial infections | 7 labelers | n/a | Yes | In shortage |
| Penicillin gpenicillin-class antibacterial | Bacterial infections | 6 labelers | n/a | No | No current entry |
| Tobramycinaminoglycoside antibacterial | Bacterial infections | 7 labelers | $0.832 per mL 80 mg/2 mL vial | No | A presentation being discontinued |
| Tigecyclinetetracycline-class antibacterial | Bacterial infections | 4 labelers | n/a | Yes | No current entry |
| Sulfamethoxazole and trimethoprimsulfonamide antimicrobial | Bacterial infections | 2 labelers | n/a | No | No current entry |
| Gentamicinaminoglycoside antibacterial | Bacterial infections | 1 labeler | $1.30 per mL 80 mg/2 mL vial | No | No current entry |
| Cilastatin and imipenemrenal dehydropeptidase inhibitor | Bacterial infections | 2 labelers | n/a | No | A presentation being discontinued |
| Erythromycinmacrolide | Bacterial infections | 3 labelers | n/a | No | No current entry |
| Moxifloxacinfluoroquinolone antibacterial | Bacterial infections | 1 labeler | n/a | Yes | A presentation being discontinued |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Ceftazidime: the full record
- label, generics, price, shortages, recalls